TransCode Therapeutics, Inc.
RNAZ
$1.78
-$0.11-5.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.75M | -17.79M | -13.44M | -4.86M | -4.28M |
| Total Depreciation and Amortization | 23.90K | 23.90K | 44.80K | 4.80K | 13.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 277.30K | 10.44M | 4.92M | 413.50K | 293.20K |
| Change in Net Operating Assets | 1.05M | 2.35M | 340.60K | 354.60K | -224.50K |
| Cash from Operations | -5.40M | -4.98M | -8.14M | -4.08M | -4.19M |
| Capital Expenditure | -- | -- | -6.70K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 2.20K | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -4.40K | -- | -- |
| Total Debt Issued | 950.00K | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 22.67M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 455.70K | -455.70K | -- |
| Cash from Financing | 950.00K | -- | 23.12M | -455.70K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.45M | -4.98M | 14.98M | -4.54M | -4.19M |